The effect of pamidronate treatment on bone health in patients with neuromuscular disease undergoing hip surgery. - Using pamidronate in patients with CP undergoing hip surgery.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-013777-17-GB

Enrollment

Registered

2010-03-17

Start date

2010-02-08

Completion date

Unknown

Last updated

2019-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children with neuromuscular conditions undergoing hip surgery. Aiming to identify whether pamidronate a licenced medicine mainatins bone mineral density in patients with neuromuscular conditions undergoing hip surgery.

Interventions

Product Name: Disodium pamidronate Pharmaceutical Form: Concentrate for solution for infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All children with neuromuscular conditions between ages 6 and 16 undergoing hip surgery and post-op immobilisation in a hip spica at Royal Manchester Children's Hospital. Exclusion criteria: Failure at screening. Not willing to participate in the study. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: To find out whether pre-operative pamidronate treatment in children with neuromuscular disorders undergoing hip surgery improves their bone strength as compared with a controlled group. ;Secondary Objective: ;Primary end point(s): Bone Mineral Content (BMC) and Bone Mineral Density (BMD) three months following surgery.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026